Over the past years, knowledge has expanded with regards to the multiple roles played by erythropoietin (EPO) in the body. Once believed to be a hormone synthesised in the kidney and involved only in the modulation of erythrocyte production, it is recognised now that EPO can be produced in many tissues, including the retina, and by many cells. In these tissues EPO is released in response to ''tissue injury" and appears to have protective functions. Despite the extensive research conducted to date, the cues leading to release of EPO and its effects in the normal and diseased retina have not been fully elucidated.
Introduction
Although initially thought that erythropoietin's (EPO) only role was the regulation of erythrocyte production in the bone marrow, it is now evident that this glycoprotein hormone plays other important functions in the body. EPO consists of 165 amino-acids (molecular mass of 30.4 kDa) which are arranged in four connected alpha helices (Davis, Arakawa, Strickland, & Yphantis, 1987; Jacobs et al., 1985; Lin et al., 1985; Miyake, Kung, & Goldwasser, 1977) (Fig. 1) . After birth, the main site of circulating EPO production is the kidney, where it is synthesised by peritubular interstitial cells in response to hypoxia (Bachmann, Le Hir, & Eckardt, 2017; Maxwell et al., 1993) . Expression of the EPO gene is stimulated by a mechanism dependent upon the hypoxia inducible factor (HIF) pathway, the chief signalling pathway involved in sensing tissue oxygen levels and adaptive responses to hypoxia, tightly regulated by the ubiquitin system [Reviewed by Jelkmann (Jelkmann, 2011)] and Günter et al. (Günter, Ruiz-Serrano, Pickel, Wenger, & Scholz, 2017) ]. In normoxia, oxygen is available and the HIF-a subunits are hydroxylated by hydroxylases [prolyl-4-hydroxylase domain (PHD) proteins 1-3 and asparagine hydroxylase factor inhibiting HIF (FIH)]. Hydroxylated HIF-a binds the von Hippel Lindau (VHL) protein which, on its turn, recruits the E3 ubiquitin ligase which catalyzes the polyubiquitination of HIF-a leading to its proteosomal degradation. In hypoxia, however, hydroxylation of HIF-a is compromised by the reduced levels of oxygen; HIF-a then combines with HIF-1b/ARNT to form the active heterodimer transcription factor HIF which stimulates the expression of the EPO gene, among others. To fulfill its role in erythropoiesis [Reviewed by Brines (Brines, 2010) ]. Expanded knowledge indicates, however, that EPO can be produced also in many tissues in response to tissue injury where it appears to exert a protective action through a different receptor, the so called innate repair receptor (IRR) [also named tissue protective receptor (TPR)] (Brines & Cerami, 2005; Brines et al., 2004) . The TPR is composed of an EPOR monomer and the b common receptor (EPOR/bCR) (Brines & Cerami, 2012) (Fig. 1) . It is expressed in the kidney, heart, muscle, endothelium, the nervous system and retina as well as in immune cells such as macrophages, among others [reviewed by Brines and Cerami (Brines & Cerami, 2012) ]. Activation of the TPR by the binding of EPO leads to phosphorylation of janus tyrosine kinase 2 (JAK-2) and, subsequently, an intracellular cascade of events including activation of STATs, PI3k/Akt, MAPKs and GSK3b which lead to reduced apoptosis, inflammation and edema (Collino, Thiemermann, Cerami, & Brines, 2015) .
Whereas EPO has high affinity for the EPOR homodimer, its affinity for the EPOR/bCR complex is low; thus, a much greater
